RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0044-1778710
Unusual Metastatic Sites of Testis and Rectum in Prostate Cancer Detected by 68Ga-PSMA-11 PET/CT Imaging at Initial Staging
Autor*innen
Funding None.
Abstract
Imaging plays a pivotal role in defining the extent of disease and deciding therapeutic strategies in recently diagnosed high-risk prostate cancer. Standard-of-care conventional imaging may often miss rare metastatic disease sites. We herein present a unique case of prostate cancer where 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) detected two unusual metastatic sites (testis and rectum) in a single patient at initial staging, resulting in an accurate determination of the extent of disease, more tailored multimodal treatment planning, and exploration of the theragnostic potential.
Keywords
prostate cancer - prostate-specific membrane antigen - 68Ga-PSMA-11 PET/CT - theranostics - metastatic disease to the testes and rectumPublikationsverlauf
Artikel online veröffentlicht:
22. Januar 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Zumsteg ZS, Spratt DE, Romesser PB. et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015; 67 (06) 1009-1016
- 2 Eggener SE, Scardino PT, Walsh PC. et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185 (03) 869-875
- 3 Mohler JL, Antonarakis ES, Armstrong AJ. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17 (05) 479-505
- 4 Wang CH, Yang S. Testicular metastasis from hepatocellular carcinoma. Int J Urol 2006; 13 (07) 1033-1034
- 5 Abou Heidar NF, Bustros G, El-Asmar JM, Sabatto BZ, Degheili JA. Isolated testicular metastasis diagnosed more than a decade and a half post primary treatment for prostate cancer. Case Rep Oncol Med 2019; 4956954
- 6 Villers A, McNeal JE, Freiha FS, Boccon-Gibod L, Stamey TA. Invasion of Denonvilliers' fascia in radical prostatectomy specimens. J Urol 1993; 149 (04) 793-798
- 7 Nwankwo N, Mirrakhimov AE, Zdunek T, Bucher N. Prostate adenocarcinoma with a rectal metastasis. BMJ Case Rep 2013; bcr2013009503
- 8 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019; 5 (06) 856-863
- 9 Hofman MS, Lawrentschuk N, Francis RJ. et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395 (10231): 1208-1216
- 10 Barbosa FG, Queiroz MA, Nunes RF. et al. Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread. Radiographics 2019; 39 (01) 186-212
- 11 Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med 2017; 58 (12) 1938-1942